These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37830930)
61. Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections. Esfahani A; Omran AN; Salehi Z; Shams-Ghahfarokhi M; Ghane M; Eybpoosh S; Razzaghi-Abyaneh M Microb Pathog; 2022 Sep; 170():105696. PubMed ID: 35921954 [TBL] [Abstract][Full Text] [Related]
62. Investigation of thiosemicarbazide free or within chitosan nanoparticles in a murine model of vulvovaginal candidiasis. Araújo DE; de Oliveira AA; Cabral MDS; Costa AF; Silva BC; do Carmo Silva L; de Menezes LB; de Almeida Soares CM; Amaral AC; Pereira M Braz J Microbiol; 2020 Dec; 51(4):1465-1473. PubMed ID: 32638273 [TBL] [Abstract][Full Text] [Related]
63. Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis. Song R; Yan F; Cheng M; Dong F; Lin Y; Wang Y; Song B Int J Nanomedicine; 2020; 15():2027-2044. PubMed ID: 32273700 [TBL] [Abstract][Full Text] [Related]
64. Use of antifungal saponin SC-2 of Solanum chrysotrichum for the treatment of vulvovaginal candidiasis: in vitro studies and clinical experiences. Herrera-Arellano A; López-Villegas EO; Rodríguez-Tovar AV; Zamilpa A; Jiménez-Ferrer E; Tortoriello J; Martínez-Rivera MA Afr J Tradit Complement Altern Med; 2013; 10(3):410-7. PubMed ID: 24146467 [TBL] [Abstract][Full Text] [Related]
65. Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. Li T; Liu Z; Zhang X; Chen X; Wang S Microb Pathog; 2019 Sep; 134():103562. PubMed ID: 31158491 [TBL] [Abstract][Full Text] [Related]
66. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. Adjapong G; Hale M; Garrill A Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642 [TBL] [Abstract][Full Text] [Related]
68. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use]. Saporiti AM; Gómez D; Levalle S; Galeano M; Davel G; Vivot W; Rodero L Rev Argent Microbiol; 2001; 33(4):217-22. PubMed ID: 11833253 [TBL] [Abstract][Full Text] [Related]
69. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Maraki S; Mavromanolaki VE; Stafylaki D; Nioti E; Hamilos G; Kasimati A Mycoses; 2019 Aug; 62(8):692-697. PubMed ID: 31132175 [TBL] [Abstract][Full Text] [Related]
70. Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. Liao H; Liu S; Wang H; Su H; Liu Z Pathog Dis; 2017 Aug; 75(6):. PubMed ID: 28645176 [TBL] [Abstract][Full Text] [Related]
71. Cai X; Kong F; Wang R; Zhai S; Guan X; Zhang G; Wang D Future Microbiol; 2019 Jul; 14():839-846. PubMed ID: 31373210 [No Abstract] [Full Text] [Related]
72. Glycogen Metabolism in Candida albicans Impacts Fitness and Virulence during Vulvovaginal and Invasive Candidiasis. Miao J; Regan J; Cai C; Palmer GE; Williams DL; Kruppa MD; Peters BM mBio; 2023 Apr; 14(2):e0004623. PubMed ID: 36840583 [TBL] [Abstract][Full Text] [Related]
73. p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis. Ferreira PS; Victorelli FD; Rodero CF; Fortunato GC; Araújo VHS; Fonseca-Santos B; Bauab TM; Van Dijck P; Chorilli M Int J Pharm; 2021 Jun; 603():120658. PubMed ID: 33964336 [TBL] [Abstract][Full Text] [Related]
74. Efficacy of vitamin B complex as an adjuvant therapy for the treatment of complicated vulvovaginal candidiasis: An in vivo and in vitro study. Sun MG; Huang Y; Xu YH; Cao YX Biomed Pharmacother; 2017 Apr; 88():770-777. PubMed ID: 28157653 [TBL] [Abstract][Full Text] [Related]
75. Vaginal homeostasis features of Vulvovaginal Candidiasis through vaginal metabolic profiling. Chen X; Wang J; Chen J; Wang G; Zhang R; Qiu J Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37573133 [TBL] [Abstract][Full Text] [Related]
76. The bacterial communities in vagina of different Candida species-associated vulvovaginal candidiasis. Chen Z; Jin J; Chen H; Chen Y; Feng S Microb Pathog; 2023 Apr; 177():106037. PubMed ID: 36842517 [TBL] [Abstract][Full Text] [Related]
77. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Fan S; Liu X; Wu C; Xu L; Li J Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649 [TBL] [Abstract][Full Text] [Related]
78. Miconazole loaded chitosan-based nanoparticles for local treatment of vulvovaginal candidiasis fungal infections. Amaral AC; Saavedra PHV; Oliveira Souza AC; de Melo MT; Tedesco AC; Morais PC; Soares Felipe MS; Bocca AL Colloids Surf B Biointerfaces; 2019 Feb; 174():409-415. PubMed ID: 30481701 [TBL] [Abstract][Full Text] [Related]
79. Development and Evaluation of Microencapsulated Oregano Essential Oil as an Alternative Treatment for Fernandes L; Barco-Tejada A; Blázquez E; Araújo D; Ribeiro A; Silva S; Cussó L; Costa-de-Oliveira S; Rodrigues ME; Henriques M ACS Appl Mater Interfaces; 2024 Aug; 16(31):40628-40640. PubMed ID: 39067028 [TBL] [Abstract][Full Text] [Related]
80. The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. Tang Y; Yu F; Huang L; Hu Z J Clin Lab Anal; 2019 Jan; 33(1):e22644. PubMed ID: 30101450 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]